<?xml version="1.0" encoding="utf-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:og="http://ogp.me/ns#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:schema="http://schema.org/" xmlns:sioc="http://rdfs.org/sioc/ns#" xmlns:sioct="http://rdfs.org/sioc/types#" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" version="2.0" xml:base="http://insureintell.github.io/">
  <channel>
    <title>cutaneous lupus erythematosus (CLE)</title>
    <link>http://insureintell.github.io/</link>
    <description/>
    <language>en</language>
    
    <item>
  <title>Cutaneous Lupus Erythematosus</title>
  <link>http://insureintell.github.io/node/25655</link>
  <description>  &lt;div data-history-node-id="25655" class="layout layout--onecol"&gt;
    &lt;div class="layout__region layout__region--content"&gt;
      
  &lt;div&gt;
    &lt;div&gt;Body&lt;/div&gt;
              &lt;div property="schema:text"&gt;&lt;p&gt;&lt;strong&gt;Note to Readers&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;This article supplements the content of our 2007 CE course on systemic lupus (SLE), where we did not have enough room to address this important topic.&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Why is this subject worth reading about?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Most underwriters know a great deal more about SLE (systemic lupus erythematosus) than they do about “skin lupus.”&lt;/p&gt;

&lt;p&gt;The intention of this article is to raise awareness of the underwriting issues in the main forms of skin lupus.&lt;/p&gt;
&lt;!--break--&gt;&lt;!--break--&gt;

&lt;p&gt;&lt;strong&gt;Is it fair to say that skin lupus and systemic lupus are the same disease?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes – the lupus is just manifesting differently.&lt;/p&gt;

&lt;p&gt;Some patients get skin disease only, whereas others get both.&lt;/p&gt;

&lt;p&gt;The “why” of this fact remains to be definitively established. [Bano]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What are the 3 main types of cutaneous (skin) lupus?&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Chronic cutaneous lupus erythematosus (CCLE), of which the only type encountered more&lt;br /&gt;
	than rarely is discoid lupus erythematosus (DLE)&lt;/li&gt;
	&lt;li&gt;Subacute cutaneous lupus erythematosus (SCLE)&lt;/li&gt;
	&lt;li&gt;Acute cutaneous lupus erythematosus (ACLE)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Does cutaneous lupus always mean skin only? &lt;/strong&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;&lt;em&gt;“The term cutaneous lupus erythematosus is applied to patients with skin lesions caused by lupus erythematosus, regardless of whether the disease is confined to the skin or represents part of a more generalized systemic disease process.”&lt;/em&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;Dimitrios T. Boumpas, MD, et al.&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Annals of Internal Medicine&lt;/em&gt;&lt;br /&gt;
&lt;br /&gt;
123(1995):42&lt;/p&gt;
&lt;/blockquote&gt;
&lt;/blockquote&gt;

&lt;p&gt;In other words, just being told it is “cutaneous” or “skin” lupus, without knowing the precise type, can mislead one into thinking a case of SLE with skin involvement is a case of skin lupus only!&lt;/p&gt;

&lt;p&gt;&lt;em&gt;Know the precise type every time!&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How common is skin involvement in systemic lupus (SLE)?&lt;/strong&gt; [Bano]&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;58% have a malar (butterfly) rash – more on this later&lt;/li&gt;
	&lt;li&gt;45% have photosensitivity (adverse response to direct sunlight)&lt;/li&gt;
	&lt;li&gt;10% will have “discoid lesions”&lt;/li&gt;
	&lt;li&gt;6% will have subacute cutaneous LE (SCLE)&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;When does skin lupus typically arise?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Ages 20-40, but it can arise at any age. [Tebbe]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is it more common in women?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes, roughly 3-4:1 in DLE (discoid) and 3-6:1 in SCLE. [Hackett, Tebbe]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What can trigger the onset of skin lupus? [Rothfield] &lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Exposure to sunlight, cold and x-ray radiation&lt;/li&gt;
	&lt;li&gt;Trauma to the skin&lt;/li&gt;
	&lt;li&gt;Skin infection&lt;/li&gt;
	&lt;li&gt;Chemical burns&lt;/li&gt;
	&lt;li&gt;Various kinds of dermatitis&lt;/li&gt;
	&lt;li&gt;Scars&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Is it significant when a proposed insured tells us he/she must wear sunblock and/or minimize sunlight exposure in some other manner on a regular basis? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Absolutely.&lt;/p&gt;

&lt;p&gt;Lupus is just one of a number of possible reasons with underwriting implications. This comment always needs to be pursued.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How is sun protection achieved in all cases of lupus?&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Avoid direct sun exposure&lt;/li&gt;
	&lt;li&gt;Sunscreens of higher potency&lt;/li&gt;
	&lt;li&gt;Tightly woven clothing, broad-brimmed hats&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Is failure to adhere to these recommendations significant?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes, for two reasons:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;It will usually result in exacerbations/worsening of skin lesions.&lt;/li&gt;
	&lt;li&gt;It speaks to a deeper issue of risk-taking in the form of non-adherence to medical recommendations, which many feel is a marker for other adverse behaviors…and there is plenty of evidence now to support this belief!&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;In what two ways has the term “discoid lupus” come to be used clinically?&lt;/strong&gt;&lt;/p&gt;

&lt;ol&gt;
	&lt;li&gt;To designate a subset of persons with skin disease only and no significant evidence of systemic involvement (which is how we tend to use the term).&lt;/li&gt;
	&lt;li&gt;To refer generically to a number of distinctive skin lesions in SLE (which, for the record, are&lt;br /&gt;
	rarely associated with aggressive forms of SLE).&lt;/li&gt;
&lt;/ol&gt;

&lt;p&gt;On balance, when the term “discoid lupus” is used, the other facts disclosed should be consistent with DLE… and NOT with SCLE, ACLE or overt SLE.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Where do discoid skin lesions usually occur?&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;They can occur anywhere but most involve the scalp, face and/or ears.&lt;/li&gt;
	&lt;li&gt;Scalp lesions occur in 60% and can be the only presentation in 10%.&lt;/li&gt;
	&lt;li&gt;The V-region of the neck is also involved in a minority of cases.&lt;/li&gt;
	&lt;li&gt;Mucosal DLE is uncommon; it may involve the mouth, nasal passages, conjunctiva and even genital mucosa. [Rothfield]&lt;/li&gt;
	&lt;li&gt;Lesions below the neck are distinctly uncommon and most that do occur are on the extensor surfaces of the arms.&lt;/li&gt;
	&lt;li&gt;When other lesions below the neck are present, the diagnosis of DLE should be questioned unless it is clearly established by biopsy.&lt;/li&gt;
	&lt;li&gt;Patients with lesions below the neck will sometimes be said to have “widespread DLE.” [Callen, 2005]&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Is the “butterfly rash” a feature of DLE? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;No – this is a RED FLAG for ACLE and systemic disease.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is cigarette smoking a risk factor for SLE? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Big time! [Miot]&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;The risk is almost 3-fold higher&lt;/li&gt;
	&lt;li&gt;Cumulative past exposure is less of an issue than current use&lt;/li&gt;
	&lt;li&gt;Smokers tend to have more extensive disease at onset&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Do DLE patients ever have positive lupus-related autoantibody tests? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Most cases do not have a positive ANA or, if they do, only a minimally increased titer in the range of 1:40. [Sontheimer, 1997]&lt;/p&gt;

&lt;p&gt;Any time the titer is higher or other autoantibodies are present, question the presumed diagnosis of DLE – &lt;strong&gt;&lt;em&gt;it is probably wrong! &lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is a biopsy always needed to diagnose DLE? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;No…but it is the only way to absolutely confirm the Dx and rule out other possible causes of the suspicious lesion. [Callen, 2006]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What % with ostensible DLE progress to SLE? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt; 7%, and most of these will be misdiagnosed cases of SCLE and/or have multiple persistent laboratory abnormalities. [Millard]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;What is the classic lesion of acute cutaneous lupus erythematosus (ACLE)?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;The “butterfly rash.” [Callen, 2005]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is ACLE usually associated with systemic disease? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes – and more often than not, relatively severe systemic disease! [Cullen, 2006]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;How does subacute cutaneous lupus erythematosus (SCLE) differ from SLE and ACLE? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;It is more extensive than SLE, typically involving the upper back and usually spares the upper neck and face.&lt;/p&gt;

&lt;p&gt;SCLE patients have chronically recurring skin disease and also often have arthralgias, malaise and other generalized symptoms which do not occur in SLE.&lt;/p&gt;

&lt;p&gt;10% of SCLE patients have central nervous system and renal disease, and for all intents and purposes represent severe systemic disease.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is SCLE more likely to have positive autoantibody tests than DLE?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes, significantly so, with 80% having an ANA positive with titer of 1:160 or higher (which is in the SLE range). Other autoantibodies associated with systemic disease are also frequently found as well. [Sontheimer, 1985]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Does Rx cause SCLE? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes, there is a huge list of drugs which can induce SCLE. None do so more than rarely.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;em&gt;ACLE and SCLE must never be confused with DLE &lt;/em&gt;&lt;/strong&gt;&lt;em&gt;– this is one of the two main issues involved in underwriting skin lupus, the other being to rule out systemic disease (SLE). &lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Why is skin lupus treated?&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;To improve the patient’s physical appearance&lt;/li&gt;
	&lt;li&gt;To prevent scarring, skin atrophy or pigmentation changes&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;How are most cases of DLE treated? &lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Topic hydrocortisone.&lt;/li&gt;
	&lt;li&gt;Intralesional injection of a steroid in very localized DLE.&lt;/li&gt;
	&lt;li&gt;If these do not work, hydroxychloroquine. However, hydroxychloroquine may also be used in the other forms of skin lupus as well as in SLE.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;What other drugs are used to treat more severe DLE as well as SCLE? &lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Retinoids such as isotretinoin.&lt;/li&gt;
	&lt;li&gt;Tacrolimus and pimecrolimus.&lt;/li&gt;
	&lt;li&gt;Thalidomide – which may be the best drug for severe cases of skin lupus; it is also used in&lt;br /&gt;
	SLE. [Cuadrado]&lt;/li&gt;
	&lt;li&gt;Chloroquine and quinacrine.&lt;/li&gt;
	&lt;li&gt;When immunosuppressives, biological agents and other SLE drugs are prescribed, you&lt;br /&gt;
	can safely bet that systemic disease is present.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Do most patients with DLE get a remission?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;If they have only head and neck disease, yes, at least 50% remit, often without recurrence of obvious/active skin lesions for many years, even decades.&lt;/p&gt;

&lt;p&gt;However, if the disease is more widespread, then &lt; 10% become clinically inactive despite Rx. [Callen, 2006]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is there any extra mortality in DLE? &lt;/strong&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;&lt;em&gt;“Discoid lupus is a chronic indolent skin disorder with no significant extra mortality.” &lt;/em&gt;&lt;/p&gt;

&lt;blockquote&gt;
&lt;p&gt;David S. Williams, MD&lt;br /&gt;
&lt;br /&gt;
Ohio National Financial Services&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Journal of Insurance Medicine &lt;/em&gt;&lt;br /&gt;
&lt;br /&gt;
37(2005):70&lt;/p&gt;
&lt;/blockquote&gt;
&lt;/blockquote&gt;

&lt;p&gt;&lt;strong&gt;What is the mortality issue in DLE? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Making certain it is discoid only…as opposed to SCLE, ACLE or DLE.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt;&lt;strong&gt;re there disability implications in DLE?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;In a German study, 45% of patients with DLE experienced “vocational handicaps,” although one would think that in those with less extensive disease this would be minimal, except perhaps in some public contact jobs. [Meller]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Are treatment costs higher in SLE than in DLE?&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Absolutely.&lt;/p&gt;

&lt;p&gt;SLE treatment cost 12-fold more dollars in one study, once the clinical workup is done and SLE is ruled out.&lt;/p&gt;

&lt;p&gt;Most of the medication used in DLE is topical and relatively cheap, compared to other drugs used in SLE.&lt;/p&gt;

&lt;p&gt;Inpatient care is rare (&lt; 3%) in DLE. Periodic visits to a community dermatologist constitute most of the care after the diagnosis is made. [Hackett]&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Is there a “WORST CASE” for DLE? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Not really (at least for mortality). However, there are scenarios which need to be carefully&lt;br /&gt;
underwritten:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Diagnosis is uncertain, especially if disease is more extensive than just on the face, scalp and/or ears (raising a question of misdiagnosis of SCLE).&lt;/li&gt;
	&lt;li&gt;Inadequate autoantibody testing, defined as not having at least an ANA test.&lt;/li&gt;
	&lt;li&gt;Persistently positive ANA ≥1:50 with a speckled or homogeneous immunofluorescent pattern. [Millard]&lt;/li&gt;
	&lt;li&gt;Presence of leukopenia or thrombocytopenia not otherwise explained.&lt;/li&gt;
	&lt;li&gt;With symptoms or other findings associated with systemic disease.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;What about the other kinds of skin lupus? &lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;ACLE should be assumed to be associated (either concurrently or eventually) with a diagnosis of systemic disease.&lt;/li&gt;
	&lt;li&gt;SCLE has a considerable risk of progressing to systemic disease.&lt;/li&gt;
	&lt;li&gt;One would think SCLE rarely acceptable “standard” (unless it has been confined to the skin for many years with consistently favorable autoantibody tests).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;Do DLE and SLE ever arise at the same time? &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Yes, rarely…and when they do, most studies show that the SLE tends to be rather mild, without lethal renal disease. [Callen, 2005]&lt;/p&gt;

&lt;p&gt; &lt;/p&gt;

&lt;p&gt;&lt;strong&gt;References&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Bano. &lt;em&gt;Clinical and Experimental Rheumatology.&lt;/em&gt; 24, Supplement 40(2006):S26&lt;br /&gt;
Callen, 2005. &lt;em&gt;Best Practice and Research Clinical Rheumatology.&lt;/em&gt; 19(2005):767&lt;br /&gt;
Callen, 2006. &lt;em&gt;Australian Journal of Dermatology.&lt;/em&gt; 47(2006):13&lt;br /&gt;
Cuadrado. &lt;em&gt;American Journal of Medicine.&lt;/em&gt; 177(2005):246&lt;br /&gt;
Hackett. &lt;em&gt;Arthritis &amp; Rheumatism. &lt;/em&gt;52, Supplement(September, 2005):S36&lt;br /&gt;
Meller. &lt;em&gt;Autoimmune Review.&lt;/em&gt; 4(2005):242&lt;br /&gt;
Millard. &lt;em&gt;Archives of Dermatology.&lt;/em&gt; 115(1979):1055&lt;br /&gt;
Miot. &lt;em&gt;Dermatology.&lt;/em&gt; 211(2006):118&lt;br /&gt;
Rothfield. &lt;em&gt;Clinics in Dermatology. &lt;/em&gt;24(2006):348&lt;br /&gt;
Sontheimer, 1977. &lt;em&gt;Lupus.&lt;/em&gt; 6(1997):84&lt;br /&gt;
Sontheimer, 1985. &lt;em&gt;The Journal of Dermatology. &lt;/em&gt;12(1985):20&lt;/p&gt;
&lt;/div&gt;
          &lt;/div&gt;

    &lt;/div&gt;
  &lt;/div&gt;

</description>
  <pubDate>Thu, 01 May 2008 04:00:00 +0000</pubDate>
    <dc:creator>hankgeorge</dc:creator>
    <guid isPermaLink="false">25655 at http://insureintell.github.io</guid>
    </item>

  </channel>
</rss>
